In late March, CNBC reported that the U.S. pharmaceutical company Eli Lilly has “reached a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market” and that Insilico has “developed at least 28 drugs using generative AI tools.”

While healthcare advocates and medical experts have heralded these developments as a boon to global healthcare, it’s critical that individuals remain cautious about medical approaches that rely heavily on AI and may be prone to abuse or may undermine human dignity.

Recent conversations within the healthcare sharing community reinforce this need for prudence. As Solidarity HealthShare’s Chris Faddis noted in a recent interview, AI is already being used across the industry in ways that can impact patient care… from streamlining administrative processes to, in some cases, influencing claim decisions or reducing human interaction. While these tools can improve efficiency, they also raise important questions about accountability, transparency, and the role of the human person in medical decision-making.

With these considerations in mind, it’s critical that faith-based health sharing ministries like Solidarity HealthShare continue monitoring the medical industry’s use of AI and its potential impact on preserving life across the nation and the world.

Solidarity’s mission has always been grounded in faith and morality, and ensuring that our Members never feel pressured to fund or support procedures or drugs they morally disagree with. While AI shows tremendous potential in advancing new, innovative treatments of disease, the medical industry must never allow AI to dodge or cancel life affirming healthcare options for the sake of expediency.

For more information about how you can join the Solidarity community, please contact our Member Care team today at 737-SHARING.